Danielle Antalffy
Stock Analyst at UBS
(3.40)
# 840
Out of 5,182 analysts
205
Total ratings
45.76%
Success rate
4.29%
Average return
Main Sectors:
Stocks Rated by Danielle Antalffy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BSX Boston Scientific | Maintains: Buy | $120 → $105 | $64.61 | +62.51% | 16 | Mar 17, 2026 | |
| SYK Stryker | Maintains: Neutral | $400 → $380 | $341.24 | +11.36% | 8 | Mar 17, 2026 | |
| SGHT Sight Sciences | Maintains: Buy | $12 → $11 | $3.91 | +181.33% | 4 | Mar 6, 2026 | |
| RXST RxSight | Maintains: Neutral | $8 → $9 | $7.22 | +24.65% | 5 | Feb 26, 2026 | |
| TNDM Tandem Diabetes Care | Maintains: Neutral | $17 → $22 | $20.66 | +6.49% | 16 | Feb 20, 2026 | |
| ATRC AtriCure | Maintains: Buy | $60 → $55 | $29.37 | +87.27% | 14 | Feb 18, 2026 | |
| ZBH Zimmer Biomet Holdings | Maintains: Sell | $88 → $86 | $94.20 | -8.70% | 7 | Jan 28, 2026 | |
| EW Edwards Lifesciences | Maintains: Neutral | $92 → $95 | $78.20 | +21.48% | 14 | Jan 12, 2026 | |
| INSP Inspire Medical Systems | Maintains: Neutral | $89 → $91 | $56.64 | +60.66% | 8 | Dec 23, 2025 | |
| GKOS Glaukos | Maintains: Buy | $140 → $145 | $121.00 | +19.83% | 3 | Dec 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $62 | $25.67 | +141.53% | 4 | Dec 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $95 → $102 | $87.10 | +17.11% | 12 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $355 → $400 | $202.50 | +97.53% | 13 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6.5 → $5.85 | $2.23 | +162.33% | 8 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $16 → $16 | $14.25 | +12.28% | 5 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $106 → $95 | $61.54 | +54.37% | 10 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $21 | $17.60 | +19.32% | 7 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $585 → $600 | $468.36 | +28.11% | 3 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $190 → $214 | $238.67 | -10.34% | 6 | Oct 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $57 | $25.33 | +125.03% | 2 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $146 → $148 | $101.56 | +45.73% | 12 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $2.25 | $4.86 | -53.70% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $975 → $825 | $4.35 | +18,865.52% | 2 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $14 | $34.76 | -59.72% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $100 | $83.94 | +19.13% | 2 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $12 | $15.61 | -23.13% | 3 | Mar 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $45 | $35.37 | +27.23% | 4 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $270 → $275 | $155.52 | +76.83% | 1 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $20 | $2.60 | +669.23% | 3 | Nov 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $72 → $42 | $6.20 | +577.42% | 7 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $60 | $6.90 | +769.57% | 3 | Apr 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $0.59 | +2,437.21% | 1 | Sep 1, 2020 |
Boston Scientific
Mar 17, 2026
Maintains: Buy
Price Target: $120 → $105
Current: $64.61
Upside: +62.51%
Stryker
Mar 17, 2026
Maintains: Neutral
Price Target: $400 → $380
Current: $341.24
Upside: +11.36%
Sight Sciences
Mar 6, 2026
Maintains: Buy
Price Target: $12 → $11
Current: $3.91
Upside: +181.33%
RxSight
Feb 26, 2026
Maintains: Neutral
Price Target: $8 → $9
Current: $7.22
Upside: +24.65%
Tandem Diabetes Care
Feb 20, 2026
Maintains: Neutral
Price Target: $17 → $22
Current: $20.66
Upside: +6.49%
AtriCure
Feb 18, 2026
Maintains: Buy
Price Target: $60 → $55
Current: $29.37
Upside: +87.27%
Zimmer Biomet Holdings
Jan 28, 2026
Maintains: Sell
Price Target: $88 → $86
Current: $94.20
Upside: -8.70%
Edwards Lifesciences
Jan 12, 2026
Maintains: Neutral
Price Target: $92 → $95
Current: $78.20
Upside: +21.48%
Inspire Medical Systems
Dec 23, 2025
Maintains: Neutral
Price Target: $89 → $91
Current: $56.64
Upside: +60.66%
Glaukos
Dec 23, 2025
Maintains: Buy
Price Target: $140 → $145
Current: $121.00
Upside: +19.83%
Dec 12, 2025
Initiates: Buy
Price Target: $62
Current: $25.67
Upside: +141.53%
Nov 19, 2025
Maintains: Neutral
Price Target: $95 → $102
Current: $87.10
Upside: +17.11%
Nov 19, 2025
Upgrades: Buy
Price Target: $355 → $400
Current: $202.50
Upside: +97.53%
Nov 7, 2025
Maintains: Neutral
Price Target: $6.5 → $5.85
Current: $2.23
Upside: +162.33%
Nov 6, 2025
Maintains: Neutral
Price Target: $16 → $16
Current: $14.25
Upside: +12.28%
Nov 3, 2025
Maintains: Buy
Price Target: $106 → $95
Current: $61.54
Upside: +54.37%
Oct 31, 2025
Maintains: Neutral
Price Target: $24 → $21
Current: $17.60
Upside: +19.32%
Oct 23, 2025
Maintains: Neutral
Price Target: $585 → $600
Current: $468.36
Upside: +28.11%
Oct 14, 2025
Maintains: Buy
Price Target: $190 → $214
Current: $238.67
Upside: -10.34%
Aug 8, 2025
Maintains: Buy
Price Target: $65 → $57
Current: $25.33
Upside: +125.03%
Jan 23, 2025
Maintains: Buy
Price Target: $146 → $148
Current: $101.56
Upside: +45.73%
Mar 29, 2023
Initiates: Neutral
Price Target: $2.25
Current: $4.86
Upside: -53.70%
May 5, 2022
Maintains: Outperform
Price Target: $975 → $825
Current: $4.35
Upside: +18,865.52%
May 5, 2022
Maintains: Outperform
Price Target: $12 → $14
Current: $34.76
Upside: -59.72%
May 2, 2022
Maintains: Outperform
Price Target: $75 → $100
Current: $83.94
Upside: +19.13%
Mar 11, 2022
Maintains: Outperform
Price Target: $15 → $12
Current: $15.61
Upside: -23.13%
Feb 25, 2022
Maintains: Outperform
Price Target: $40 → $45
Current: $35.37
Upside: +27.23%
Feb 4, 2022
Maintains: Market Perform
Price Target: $270 → $275
Current: $155.52
Upside: +76.83%
Nov 10, 2021
Maintains: Outperform
Price Target: $26 → $20
Current: $2.60
Upside: +669.23%
Nov 5, 2021
Maintains: Market Perform
Price Target: $72 → $42
Current: $6.20
Upside: +577.42%
Apr 1, 2021
Downgrades: Market Perform
Price Target: $60
Current: $6.90
Upside: +769.57%
Sep 1, 2020
Initiates: Outperform
Price Target: $15
Current: $0.59
Upside: +2,437.21%